TFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TRANFA pplication of : Anderskewitz, R., et al ) Art Unit: 1624 U.S. Appln. No. : 10/771,756 ) Examiner: Confirmation No.: 3647 U.S. Filing Date: February 4, 2004 Title of Invention: Pyrrolidinohydrochinazolines Attny. Docket No.: 1/1456 Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 September 21, 2004 TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT Sir: Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow. X 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114. This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by: A statement as specified in 37 C.F.R. §1.97(e) [see below]; or The fee set forth in 37 C.F.R. §1.17(p).

		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.				
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.				
	1.97(e	).				
	counte	Each item of information contained in the instant information disclosure tent was first cited in any communication from a foreign patent office in a expart foreign application not more than three (3) months prior to the filing of stant information disclosure statement; or				
	No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a coun foreign application, and, to the knowledge of the person signing this certificate making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 3 §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.					
		The fee set forth in 37 C.F.R. §1.17(p).				
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.				
counte n sect	rpart ap	(d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated 6(c) more than thirty (30) days prior to the filing of the accompanying isclosure statement.				

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Anthony P. Bottino

Attorney for Applicant(s)

Reg. No. 41,629

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 791-6764 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on September 21, 2004.

Anthony P. Bottino, Reg. No. 41,629

O 1 P E SEP 2 3 2004

PTO/SB/08b (08-03)
Approved for use through 06/30/2006, OMB 0651-0031

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO Complete if Known Application Number 10/771,756 Filing Date INFORMATION DISCLOSURE February 4, 2004 First Named Inventor STATEMENT BY APPLICANT Anderskewitz, R., et al Art Unit 1624 (Use as many sheets as necessary) Examiner Name To be assigned Sheet Attorney Docket Number 1/1456

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		MOLINA, Pedro et al; Inhibition of Leucocyte functions by the alkalois isaindigotone from Isatis indigotica and some new synthetic derivatives, Journal of Natural Products, vol. 64, no. 10, 2001, XP002286635, example 1	
		RIOJA, Immaculada, et al; "A pyrroloquinazoline derivative with antiinflammatory and analgesic activity by dual inhibition of COX-2 and 5-lipooxygenase" European Journal of Pharmacology, vol. 434, no. 10, 2002, XP 002286636 figures, example 1	
••••••••••••			
	••••••		
	•••••••		
	•••••		., ,
Examiner		Date	<u></u>

Examiner Signature		Date Considered	
Signature		Considered	
	 - · · · · · · · · · · · · · · · · · · ·		 

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.